Skip to main content

Table 2 Comparison of HCCs showing a complete response according to mRECIST with complete and incomplete lipiodol retention

From: Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response

 Incomplete (N = 16)Complete
(N = 30)
p value+
Serum AFP level (μg /L) ± SD44 ± 11093 ± 2790.50
HCC Size (mm) ± SD22.9 ± 0.822.8 ± 100.96
HCC location  1.00
 - Left lobe5 (32%)10 (33%)
 - Right lobe11 (68%)20 (66%)
Capsule appearance4 (25%)9 (30%)0.50
Selective cTACE Treatment10 (62%)23 (76%)0.24
Mean Delivered Dose (mg) ± SD22 ± 1126 ± 130.54
Embolic agent   
 - Gelfoam14 (87%)26 (86%)0.22
 - PVA particles0 (0%)3 (10%)
 - None2 (13%)1 (4%)
CBCT guidance9 (56%)17 (56%)0.61
Local progression*15 (94%)10 (30%)<0.01
Mean delay of local progression (months) ± SD11.1 ± 213.4 ± 30.51
  1. *median follow-up of 14 months (range 3.2–35.9 months)
  2. + Chi2 test and t-test were used for analysis of discrete and continuous variables respectively
  3. AFP Alpha-fetoprotein, CBCT Cone beam computed tomography, HCC Hepatocellular carcionoma, PVA Polyvinyl alcohol, SD Standard deviation, cTACE Conventional transarterial chemoembolization
  4. significant differences are bold